Read our latest updates & insights

Pfizer notifies the CHMP it wishes to withdraw its application for Fyzoclad®, biosimilar adalimumab, due to changes in the company’s strategy.  

The EMA accepts Celltrion’s application for a subcut formulation of biosimilar infliximab, Remsima SC®.

At the ASH Annual meeting, a paper was presented indicating positive results for Sandoz’s proposed RmAb biosimilar to EU reference drug, and concluding “efficacy, safety and immunogenicity, PK and PD of PF‑05280586 and rituximab-EU were similar up to Week 26 in ...

AbbVie announces a 7th global deal for biosimilar adalimumab. A non-exclusive royalty bearing license to Pfizer for AmAb will begin on 20 November 2023 in the US and on approval in the EU (no other dates disclosed).  Pfizer’s US launch date is the same as Momenta̵...

Tanvex announces that the FDA has accepted its BLA for biosimilar filgrastim.

FDA approves Celltrion’s rituximab biosimilar CTP-10 (Truxima®), for the treatment of non-Hodgkin’s lymphoma. This is the first US biosimilar RmAb to be approved.

Daiichi Sankyo launches first trastuzumab biosimilar in Japan.

Sandoz announces EC marketing approval for pegfilgrastim biosimilar Ziextenzo®.

EMA approves biosimilar pegfilgrastim Pelmeg® for patients undergoing cytotoxic chemotherapy for malignancy, with the exceptions of chronic myeloid leukaemia and myelodysplastic syndromes.

Fuji Pharma and Alvotech announce exclusive partnership agreement for the commercialisation of Alvotech’s biosimilars in Japan. Fuji Pharma will be responsible for the registration and commercialisation of products, while Alvotech will be responsible for development a...